The American Cancer Society (ACS) estimates that 228,150 new cases of lung cancer will be diagnosed in the United States in 2019 with an estimated 142,670 estimated deaths, with smoking remaining an important risk factor. The emergence of new biomarker testing, advances in radiation techniques, and the availability of new systemic therapies has changed the treatment landscape for non-small cell lung cancer.  This rapid pace of development and evolution has created challenges for clinicians to remain current with the advances in treatment options and the management of adverse events resulting from these new therapies. The NCCN 2019 Congress Series™: Lung Cancer is designed to familiarize clinicians with key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), new and emerging therapeutic options, the latest clinical research on lung cancer, and how these advances compare to the current standard of care to optimize management of patients with lung cancer and assist practitioners to incorporate new cancer treatment strategies and regimens into their practice.

Congress Goal: The goal of this congress is to ensure that physicians, nurse practitioners, nurses, pharmacists, physician assistants, and other relevant healthcare professionals who manage the care of patients with lung cancer have the knowledge and skills necessary to apply the standards of care to their practice and healthcare settings.

Details

Hosted by: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  • When

  • Friday, November 8, 2019
    8:30 AM - 2:45 PM

  • Where

  • The Koch Cancer Research Building
    Albert H. Owens Jr. Auditorium
    1550 Orleans Street
    Baltimore, Maryland 21231

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top